Literature DB >> 12407024

HY peptides modulate transplantation responses to skin allografts.

Edward James1, Diane Scott, Jian-Guo Chai, Maggie Millrain, Phillip Chandler, Elizabeth Simpson.   

Abstract

Injection of female C57BL/6 mice with immature female bone marrow-derived dendritic cells (BMDC) pulsed with a single immunodominant HY(Db) Uty peptide, WMHHNMDLI, induces prolonged survival of syngeneic male skin grafts. In contrast, injection of immature female BMDC pulsed with a single MHC class I-restricted HY(Ab) Dby peptide, NAGFNSNRANSSRSS, causes immunization similar to that following injection of male cells. Tolerance induced by HY(Db) Uty peptide pretreatment is not characterized by clonal deletion: long-term tolerant mice maintain circulating HY(Db) Uty tetramer(+) T cells which expand following exposure to male cells in vivo or in vitro. Tolerance to male skin grafts can be adoptively transferred into neonatal females with splenocytes from tolerant donors. Tolerance is specific-third-party skin grafts are rejected. We propose that tolerance in this model is initiated by cognate interaction of HY(Db) Uty-specific CD8(+) T cells with their ligand, presented either on the injected immature BMDC or on recipient DC. This interaction leads to incomplete activation of the CD8(+) T cells resulting in diminished responsiveness of CD4(+) and CD8(+) T cells specific for HY peptide epitopes subsequently presented on the male graft.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407024     DOI: 10.1093/intimm/dxf093

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  8 in total

1.  Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Authors:  E Andreakos; R O Williams; J Wales; B M Foxwell; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

2.  CD8+ regulatory T cells generated by neonatal recognition of peripheral self-antigen.

Authors:  Roland Reibke; Natalio Garbi; Ruth Ganss; Günter J Hämmerling; Bernd Arnold; Thilo Oelert
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-28       Impact factor: 11.205

3.  Molecular mechanisms of induction of antigen-specific allograft tolerance by intranasal peptide administration.

Authors:  Katy Derbyshire; Caroline Addey; David Coe; Daniel W Stuckey; Hasan Muezzin; Jason A Bubier; Daniel J Shaffer; Derry C Roopenian; Jian-Guo Chai; Diane M Scott
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

4.  Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.

Authors:  Kelan A Hlavaty; Derrick P McCarthy; Eiji Saito; Woon Teck Yap; Stephen D Miller; Lonnie D Shea
Journal:  Biomaterials       Date:  2015-10-21       Impact factor: 12.479

5.  Ethylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer histocompatibility Y chromosome antigen transplant protection by inhibiting CD154 upregulation.

Authors:  Aaron J Martin; Derrick McCarthy; Carl Waltenbaugh; Gwen Goings; Xunrong Luo; Stephen D Miller
Journal:  J Immunol       Date:  2010-08-16       Impact factor: 5.422

6.  The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants.

Authors:  Govindarajan Thangavelu; Kenneth M Murphy; Hideo Yagita; Louis Boon; Colin C Anderson
Journal:  Immunobiology       Date:  2011-01-12       Impact factor: 3.144

7.  Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation.

Authors:  M Segovia; C Louvet; P Charnet; A Savina; G Tilly; L Gautreau; L Carretero-Iglesia; G Beriou; I Cebrian; T Cens; L Hepburn; E Chiffoleau; R A Floto; I Anegon; S Amigorena; M Hill; M C Cuturi
Journal:  Am J Transplant       Date:  2014-04-14       Impact factor: 8.086

8.  Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles.

Authors:  Young Jik Kwon; Stephany M Standley; Sarah L Goh; Jean M J Fréchet
Journal:  J Control Release       Date:  2005-07-20       Impact factor: 9.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.